A Review on the Status of Breast Cancer Care in Tanzania

Hidaya Mansouri1,2,*, Amos R. Mwakigonja3, Faith A. Rodgers4, Emmanuel A. Mpolya1, Elingarami Sauli1

1 Department of Global Health and Bio-Medical Sciences (GHBM), Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania
2 African Union Scientific Technical and Research Commission (AU-STRC), Abuja, Nigeria
3 Department of Pathology, Muhimbili University of Health and Allied Sciences (MUHAS), Dar es Salaam, Tanzania
4 Department of Economics, College of Social Sciences (COSS), University of Dar es Salaam, Dar es Salaam, Tanzania

*Corresponding author: Hidaya Mansouri, Department of Global Health and Bio-Medical Sciences (GHBM), Nelson Mandela African Institution of Science and Technology (NM-AIST), P. O. Box 447, Arusha, Tanzania. Tel: +2552693333609; E-mail: mansouri1210dayi@gmail.com

INTRODUCTION

The major challenges of breast cancer (BC) care in low- and middle-income countries (LMICs) including Tanzania are early diagnosis and disease prevention, as well as providing the patients with pre- and post-therapies at effective cost. BC is second to cervical cancer (CC) in Tanzania due to its high mortality rate, poor survival and the fact that it affects both females and males similarly and negatively impacts the economically active population. The current review study was conducted to understand the status of care services directed at this disease in Tanzania. Since its independence in the early 1960s, Tanzania has continued to maintain socio-political stability and economic growth among different sectors, thus

Keywords:
Breast Cancer
Noncommunicable Diseases
Tanzania
Health Services

Tanzania continues to enjoy stability and growth in different sectors similar to other countries; however, some challenges persist in the health sector, especially in the area of cancer care. The current study aimed at reviewing social economic status (SES), as well as factors contributing to the increased burden of breast cancer (BC) in Tanzania. The current study reviewed different literature ranging from nationally/internationally published statistics, academic publications, health information of non-governmental organizations, academic researchers, and other sources of health information to better understand the socioeconomic and BC care status in Tanzania. The current review showed that BC is still the second most prevalent malignant disease in Tanzania, and most of the patients referring to medical centers are in the advanced stage of the disease due to shortage and unaffordability of health care services. The majority of health-related interventions and investments target infectious diseases, including HIV-AIDS, tuberculosis, malaria, as well as maternal and child health-related conditions, compared to noncommunicable diseases (NCDs) such as BC. In spite of some setbacks and improvements in healthcare facilities (e.g., novel techniques for early detection), the best way to address BC care is affordable fees for clinical and laboratory investigations, accessible treatment, palliative care, follow-up, rehabilitative care, and better management and allocation of resources.
providing more support to foreign investors compared to its neighboring countries. With an estimated population of 52 million, Tanzania’s population grows at an annual rate of 2.3%-2.7%, triggering the rise in demand for social comforts and infrastructure according to the 2012 Population and Housing Census [1, 2]. As claimed by the Business Monitoring Intelligence and the National Bureau of Statistics, a robust economic growth based on the infrastructure investment in standard-gauge electrical railways, ports, and harbors, as well as expansion and improvement of roads are expected to be among the main drivers of gross domestic product growth from 2017 to 2026, with a constant average of around 6.2% [1, 3]. Following the Deloitte Touché Tohmatsu Limited report in 2016 and The Citizen Tanzania newspaper in 2018, despite the promising implementation and growth in telecommunication (via mobile financial service), agriculture and industrialization focusing on agricultural food processing and employment of about 65% of the population [1, 4], certain gaps in the public health system still exist, including poor water, hygiene, and sanitation as well as health care facilities, which may contribute negatively to the perceived socio-economic status of the country. Due to increased incidence (7.2%) and number of deaths occurring each year, BC becomes the second major public health concern for women worldwide, specifically in Tanzania, which is often diagnosed in an advanced stage largely due to lack of reliable screening settings, early detection, and thus, making it fatal for 56% of the women diagnosed according to the Foundation of Cancer Care in Tanzania. Despite being the second cause of death among women after CC in Tanzania, BC incidence is higher in LMICs, where case-fatality rates are disproportionately higher. The current study aimed at reviewing the current status of BC care in Tanzania, focusing on involved socioeconomic factors and identifying possible diagnostic and prognostic targets and treatment affordability in the country. For this purpose, a review of the literature was conducted on related academic publications, health information data of non-government organization/civil societies, health care institutions, academic research, and other health-related sources (MEDLINE and Google Scholar), for better understanding of BC, socio-economic, and health status in Tanzania (Figure 1).

### Figure 1: Assessment of Literature Review

**Health Status**

The healthcare sector funding in Tanzania and other LMICs is steadily increased over the years, as reflected by the continuous expansion of services, as well as the quality of care; although there is still plenty of room for further improvement [5], including the possibility for increasing healthcare spending per capita from about US$44 currently to at least US$54, as recommended for the developing countries by the high-level Taskforce on Innovative International Financing for Health Systems [1, 6]. Notably, communicable diseases; maternal, newborn, and childhood illnesses; other disease-e.g. neglected tropical diseases; noncommunicable diseases (NCDs); and malnutrition are among the main causes of morbidity and mortality in the country [7-10]. Under such circumstances, it is therefore desirable that the demand on healthcare delivery system at all levels in terms of drugs, equipment, and medical supplies be matched with a corresponding level of funding, in order to allow sustainability in healthcare provision. Such a level of funding helps to prevent deterioration of the physical health care infrastructure, including public utilities (energy, water, and sanitation), and the supply of health-related logistics at the healthcare facilities, following the African Health Observatory and UNICEF report [6, 11, 12]. Furthermore, the availability of requisite funding might support and sustain poor healthcare management in addition to the regulatory frameworks, wages, and other incentives for healthcare workers [13]. Naturally, improved funding results in improved health care, which subsequently results in a decreased burden of disease in the country and ultimately increased
productivity [3, 6, 12]. Since women make the majority of productive force in LMICs such as Tanzania, improved BC care directly and positively impacts productivity and economic growth thus results in the improved community, as well as individual welfare.

**Burden of Noncommunicable Diseases**

Broadly speaking, there is an evidence of the increased global burden of NCDs, particularly in developing countries such as Tanzania, compared with developed ones - e.g. USA, Eastern Mediterranean, and Europe [14, 15]. In Tanzania, NCDs, such as cardiovascular diseases, chronic respiratory diseases, diabetes, cancer, and injuries, are reported as the major public health issues that significantly contribute to increased mortality and morbidity across all age groups and genders [14, 16] (Figure 2 and Figure 3).

Numerous factors, including modifiable (i.e. tobacco use, unhealthy diet, insufficient physical activities, alcohol consumption, occupation, etc.) and non-modifiable factors (i.e. aging, gender, race, and genetic dynamics) contribute to increased disease burden [19-21]. Following the World Health Organization (WHO) STEPwise approach to Surveillance conducted in Tanzania from 2012 to 2013, statistics showed that 14.1% of the population were tobacco smokers, 29.3% were associated with alcohol consumption, 26% were overweight and hypertensive, and only 2.8% followed a healthy diet [22]. As a result, many people spend their non-standard form of employment revenue for diverse healthcare needs. Urgent measures should then be taken in order to mitigate the burden of NCDs in developing countries including Tanzania [8-10].

**Cancer Burden**

Cancer is one of the major life-threatening diseases in the world. Globally, BC is the most frequently diagnosed malignant disease and the leading cause of cancer death among females, accounting for 23% of the total cases and 14% of the cancer deaths [16, 23, 24]. The current report from WHO estimated that more than 17 million new cancer cases were diagnosed, with more than 9 million accounting for death [25]. According to gender, lung cancer (2.1 million cases) and prostate cancer (1.2 million cases) are the first and most common cancers globally among males, with more than 1.5 million deaths annually. With more than 2 million cancer cases among females, the most commonly encountered cancers are CC, BC, and colorectal cancer, all being responsible for up to 522,000 deaths worldwide every year [26, 27]. However, BC was the second cause of death among females in Tanzania, following CC in 2012, with approximately 2732 (14.4%) newly diagnosed cases [28, 29]. Over the years, the status of BC disease remained unchanged in Tanzania in contrast to developed countries (Figure 4, Figure 5, and Figure 6). It was partly due to limitations in timely screening, early diagnosis, low availability of immunohistochemistry (IHC) test for receptor status, and lack of cancer registries. The fact that individuals still seek traditional health remedies in this part of the world instead of conventional medicine increases the burden, thus causing delayed diagnosis and treatment, as well as underreporting [16, 28, 30-34].
Most of the time, many diseases, including BC, are diagnosed at a late/advanced stage in most developing countries, resulting in the inability to reduce the frequency and consequences of the disease [16, 28, 30-33]. It is thus a challenging, but noble and important task to find appropriate strategic plans to diagnose (including molecular tests) and effectively treat BC, and reduce its incidence [35].

**Non-Molecular Breast Cancer Screening Approaches in Tanzania**

Surgery was the predominant and standard treatment for BC in the past century until the past decade. However, treatment modalities underwent drastic changes over the years due to novel research discoveries, which include elucidation of more prognostic factors, histological and immunohistological characterization, and cytogenetic diagnosis, leading to a wider range of therapeutic options, including customized/targeted therapies. Self-examination characterized by a palpable mass or lump most frequently located in the upper outer quadrant of the breast, nipple discharge, peau d’orange, skin ulceration, and fungating mass are most often discovered by the patient [37, 38]. Besides, mammography screening is one of the conventional examination techniques, providing information about prognostic factors (tumor size, lymph-node involvement, and metastasis) helping to classify a patient with benign condition or malignancy. Comprehensive molecular profiling of tumors is widely studied over the past few years in a variety of cancers, leading to the development of a new discipline termed “personalized medicine” [34, 37-39].

**Molecular Biomarker Screening of Breast Cancer in Tanzania**

Numbers of proteins and germline markers for BC are identified, qualified for clinical examination, validated, and reported by the National Comprehensive Cancer Network (NCCN) for which the targeted drugs are discovered and exploited; the proteins include estrogen receptors (ER), progesterone (PR), human epidermal receptor (HER-2), the BRCA1/2, PIK3CA, PD-L1, and tumor suppressor (p53) [40]. Other proteins such as Ki-67 and anti-apoptotic cell protein (BCL-2) also attracted the attention of researchers; although they were also studied as potential prognostic markers of BC, they are not recommended for clinical assessment by NCCN yet. Although many laboratories and medical centers do not assess molecular profiles of BC, such as ER, PR, and HER-2 as standard procedure for patients in Tanzania, studies show the
correlation of Ki-67, p53, and BCL-2 with clinical presentations of the disease such as histopathology grade and prognosis among patients, regardless of their low applicability in clinical trials [35, 41-43]. The p53 is an oncoprotein (also called TP53) encoded by p53 tumor suppressor gene that normally limits cell growth by monitoring quickly dividing cells, restoring inconsistent DNA, and regulating apoptosis, but it is also a key prognostic marker in the early detection of BC [35, 44, 45]. Moreover, BCL-2, on the other end, is an anti-apoptotic cell protein encoded by the BCL-2 gene with an imperative effect on cell survival through inhibiting the pro-apoptotic antigen activity. The BCL-2 is also associated with hormone receptor status due to its manifestation in normal breast glandular epithelium and upregulation by estrogen [46-48]. Besides, Ki-67, p53, and BCL-2 are the most significant and helpful predictive variables presently accessible for endocrine treatment targets [35, 43, 49, 50]. Further studies and investigations on molecular markers are required for therapeutic success. This can only be sustained through the strengthening of clinical settings, as well as laboratory facilities and services, leading to effective treatment.

Breast Cancer Diagnosis and Treatment Services in Tanzania

BC screening and diagnosis involve self-observation, physical examination by a physician, breast ultrasonography, mammography, FNAB/FNAC, and core-needle biopsy (or incisional biopsy where cores are not available), as well as chest radiography to rule out metastasis once the cancer is confirmed [51]. In addition, where the core-needle biopsy is not available and patients do not express or respond to endocrine therapy, FNAC smears coupled with cell blocks as well as more target molecular markers could have a comparable diagnostic value in addition to their economic advantages. Most often, the treatment and diagnosis of BC require multiple healthcare facilities and professionals—i.e., clinicians (surgeons, oncologists, and others), ultra-sonographers, radiographers, radiologists, pathologists or cytologists, histotechnologists, cytotechnologists, or a general lab scientist as an alternative [32, 52, 53]. These highly-skilled professionals might not be readily available and accessible to many individuals in need of BC diagnostic services in LMICs. Some of the laboratory procedures are available in Tanzania, including fine-needle aspiration biopsy / cytology (FNAB/FNAC) and core-needle biopsy utilized for tissue microarrays (TMAs). These methods need to be optimized to allow early and accurate BC diagnosis in more medical centers [54, 55]. Moreover, the routine IHC test for BC receptors at molecular levels (ER, PR, and HER2) used as the most early, rapid, accurate, and cost-effective diagnostic measure for BC is currently available at the Histopathology Unit of the Central Pathology Laboratory of Muhimbili National Hospital (MNH) in Dar es Salaam [29, 33, 35]. However, there are only about five regions in Tanzania that currently have at least one pathologist as well as surgical pathology/cytology services [32]. The current practice to treat BC in Tanzania depends on the stage of the disease and includes neoadjuvant therapy, followed by mastectomy or mastectomy with adjuvant therapy [51]. Patients destined to experience recurrence can be candidates for systemic adjuvant therapy, and the ones who are not at the risk of recurrence do not require adjuvant therapy, which is cost-effective to the health system. Such decisions are made by the specialists of both MNH and Ocean Road Cancer Institute (ORCI) through a multidisciplinary tumor board. Patients with BC are generally categorized as premenopausal and postmenopausal. However, both categories are treated with surgery, chemotherapy, radiotherapy, and hormonal therapy [tamoxifen—a selective estrogen receptor modulator (SERM)], depending on the stage of the disease and expression level of hormone receptors (HR) [16, 30, 35, 51, 56]. On the other hand, for postmenopausal women not responsive to tamoxifen (an anti-HR drug), an aromatase inhibitor (AI) drug (Anastrozole) is currently prescribed at MNH alongside surgery and chemotherapy. Radiotherapy is given as well when surgical margins and regional lymph nodes are positive for tumor. Other forms of hormonal manipulation, including selective estrogen receptor degrader (SERD like fulvestrant) and luteinizing hormone-releasing hormone (LHRH) analogs such as zoladex are not yet used to treat BC in MNH, although zoladex is currently used to treat prostate cancer. However, the medical fraternity in MNH should also consider the possibility of adding zoladex just like anastrozole to tamoxifen non-responders,
as it is already available locally. In addition, patients strongly overexpressing the HER2 marker may be eligible for receiving an immunotherapeutic monoclonal antibody agent such as trastuzumab or herceptin as well.

Tanzania is one of the few countries in the Eastern, Central, and Southern African sub-region that has a well-established and longstanding cancer treatment institute, named ORCI. Furthermore, new and upcoming oncology centers are at different stages of the establishment at Bugando Medical Center (BMC) in Mwanza, as well as the Kilimanjaro Christian Medical Center (KCMC) in Moshi; although they may not be still sufficient to serve the whole Tanzanian population, majority of those may also be rural-based [32, 52]. Nevertheless, this is no small feat including the fact that these centers serve the neighboring countries. This situation makes cancer diagnosis and therapy still expensive for many ordinary Tanzanians. Patients with BC in the lake regions (around Mwanza) are relatively younger premenopausal women mostly referring to medical centers at advanced stage of the disease and high rate of lymph-node metastasis [57]. Altogether, this makes BC care (including cancer diagnosis generally) a complex, multistep, and multicentric practice, with subsequent high-cost implications to the patient and/or his/her family and the country as a whole. This may be economically prohibitive to the underprivileged patient. Hospital-seeking behavior is also determined by the educational and socioeconomic status of the patient and/or his/her family. Consequently, a significant number of patients seek traditional remedies/healers only or prior to consulting conventional medicine, resulting in delayed diagnosis, advanced stage of the disease at diagnosis, and poor outcome of treatment. There is a need therefore to improve public awareness on BC, including setting up screening centers to promote early detection and thus allowing timely intervention [16, 31, 32, 58].

Limited Access to Breast Cancer Care and Tumor Markers Testing in Tanzania

One of the constraints on BC diagnosis in Tanzania is the molecular characterization of tumor markers in patients. Several investigations put forward that African BC is largely caused by overexpression of hormone receptors [59]. Pathologists and researchers working in low-resource countries face challenges with regard to Standard Operating Procedures (SOPs) for IHC staining due to many reasons, including outperformance of surgery, pretreatment of tissue samples, low-quality specimens from large and necrotic tumors, doubtful quality of fixative materials, a lengthy stay in the fixative agent (regularly for several weeks), poor laboratory techniques and low-quality assurance/quality control practices, which often lead to the inapplicability of advanced IHC techniques [60]. In Tanzania, there is a small number of studies on BC diagnosis using IHC or other techniques for the assessment of BC molecular markers such as Ki-67, p53, and BCL-2 [31, 33, 35, 61]. In total, there are 169 district hospitals and 30 regional referral hospitals in which four are public referral and zonal hospitals including MNH for the coastal zone, Mbeya Referral Hospital in the Southern highlands zone, BMC in the lake zone, and KCMC in the Northern zone [32]. Unfortunately, not all healthcare activities related to BC care are conducted as planned, since most of them face limited human resources and poor supply of important health commodities. The four public referral and zonal hospitals, as well as Aga Khan Hospital (AGH), are the most prominent medical centers offering cancer screening and diagnostic services. However, chemotherapy and palliative therapy are only offered by ORCI. Moreover, most of these centers lack diagnostic facilities such as the IHC technique. All patients with cancer in the regional and peripheral zones are directed to MNH for hormonal receptors and Her-2 examination or other IHC tests. This institution offers an original assessment of BC categories in Tanzania, where they lack a population-based registry [30, 32]. This limitation on facilities with IHC capacity calls for government efforts to provide IHC facilities to the abovementioned centers. Burson et al., (2010) performed a two-year survey in Tanzania using medical records of patients with BC admitted to ORCI from July 2007 to June 2009. Their results revealed that the frequency or molecular characteristics of BC in Tanzania are scarcely understood [30]. The MNH provides radio- and chemo-therapy for patients with BC in partnership with ORCI. However, this collaboration offers an extremely specific treatment in both overcrowded clinics with long waiting times for critical practices such as surgery and pathological assessment [32], making treatment outcomes hardly sensitive. Improvement of healthcare facilities
for early diagnosis and management of cancer is therefore imperative. A study in 2017 by the Ministry of Health, Community Development, Gender, Elderly, and Children (MoHCDGEC) of Tanzania showed that the fraction of patients with BC expressing hormone receptors in the various medical center could be substantial and significantly affected by therapeutic plans (endocrine therapy) [32]. But the current queries are: if patients are not substantial for endocrine therapy, how are other prognostic biomarkers, such as Ki-67, p53, and BCL-2, expressed vis-à-vis the age, stage, and grade in patients with BC in these specialized hospitals? Is there any correlation between the expression of these biomarkers and clinical and histopathological features of BC cases admitted to MNH? These further questions were partly addressed in a research study conducted by Mansouri et al., (2019), where a significant association among biomarkers (Ki-67, p53, and BCL-2) expression and clinico-histopathological features (age, tumor grade, stage of the disease, tumor size, and lymph-node status) of BC were observed [35]. However, further studies are required to comprehensively elucidate the association of BC biomarkers, the pathogenesis, histopathology, prognosis and therapeutic options to improve patient care and wellbeing and positively enhance the socioeconomic status of patients, the community and country as a whole. Furthermore, the future of BC care in developing countries should include targeted therapeutic modalities based on cytogenetics and other ancillary molecular diagnostics, including gene microarrays [7, 62]. These might serve as the second frontline in the quest for improved care and outcome of patients with BC in Tanzania.

CONCLUSIONS

BC is still a global public health concern, but mostly in developing countries such as Tanzania where a significant proportion of the population may also be affected by poverty and limitations in availability, accessibility, and affordability of appropriate healthcare services. The healthcare system of the country needs to be strengthened particularly in the area of cancer diagnosis and care. To positively affect the survival of patients with BC through personalized therapy systems, BC management in Tanzania should discover routes to improve the pathology facilities, including IHC for screening biomarkers in a regular cancer management process. The increased investments in the healthcare system, including novel and pre-existing techniques for early detection of BC and other cancers, affordable laboratory diagnostic fees for patients, availability of comprehensive and customized treatment modalities and palliative care, improved patient follow-up and management, and generally the allocation of resources could be the best way to tackle this particular health challenge and improve the quality of life of patients and thus positively affect the productivity.

ACKNOWLEDGMENTS

The author wishes to thank the different institutions including The Nelson Mandela African Institution of Science and Technology (NM-AIST), Muhimbili National Hospital (MNH), and the Muhimbili University of Health and Allied Sciences (MUHAS) for hosting the author during the accomplishment of this work.

CONFLICT OF INTEREST

The authors declared no conflict of interest.

ETHICS APPROVAL

Not applicable.

REFERENCES

1. Deloitte Touche Tohmatsu Limited. Tanzania Economic Outlook 2016. The Story Behind the Numbers Deloitte Touche Tohmatsu Limited; 2016 [updated 2016 June; cited 2020 June 27]. Available from: https://www2.deloitte.com/content/dam/Deloitte/tz/Documents/tax/Economic%20Outlook%202016%20TZ.pdf.

2. National Bureau of Statistics, Ministry of Finance, Office of Chief Government Statistician, President’s Office: Finance; Economy and Development Planning. 2012 Population and Housing Census. Population Distribution by Administrative Areas. Dar es Salaam, The United Republic of Tanzania: National Bureau of Statistics, Ministry of Finance, Office of Chief Government Statistician, President’s Office, Finance, Economy and Development Planning, Zanzibar; 2013. 264 p.

3. Economic and Social Research Foundation, United Nations Development Programme, Government of the United Republic of Tanzania: Ministry of Finance and Planning. Tanzania Human Development Report 2017: Social Policy in the Context of Economic Transformation. United Republic of Tanzania: Economic and Social Research Foundation, United Nations Development Programme, Ministry of Finance and Planning; 2018. 138 p.
4. Leliveld A, Dietz T, Klaver W, Kilama B, Foeken D, Akin-oyoade A, et al. Agricultural dynamics and food security trends in Tanzania. London/Leiden: African Studies Centre, 2013 December. Report No.: 2013-ASC-3.

5. Piot P, Caldwell A, Lampetey P, Nyirirenda M, Mehra S, Cahill K, et al. Addressing the growing burden of non-communicable disease by leveraging lessons from infectious disease management. J Glob Health. 2016;6(1):010304. DOI: 10.7189/jogh.06.010304 PMID: 26955469.

6. World Bank, UNICEF, UNFPA. Health Systems for the Millennium Development Goals: Country Needs and Funding Gaps. Background document for the Taskforce on Innovative International Financing for Health Systems. The United Republic of Tanzania: World Bank, UNICEF, UNFPA, Partnership for Maternal, Newborn and Child Health; 2009. 150 p.

7. Elingarami S. Cancer: Incidence, Molecular Biology and Future Research Direction. Adv Sci Lett. 2011;4(1):21-30. DOI: 10.1166/asl.2011.1945.

8. Shayo FK. Co-occurrence of risk factors for non-communicable diseases among in-school adolescents in Tanzania: an example of a low-income setting of sub-Saharan Africa for adolescence health policy actions. BMC Public Health. 2019;19(1):972. DOI: 10.1186/s12889-019-7320-1 PMID: 31331303.

9. Mayige M, Kagarku G, Ramaiya K, Swai A. Non communicable diseases in Tanzania: a call for urgent action. Tanzan J Health Res. 2011;13(Suppl 1):378-86. DOI: 10.4314/thbr.v13i15s7 PMID: 26591992.

10. Roman WP, Martin HD, Sauli E. Assessment of risk factors for cardiovascular diseases among patients attending cardiac clinic at a referral hospital in Tanzania. J Xiangya Med. 2019;4:18. DOI: 10.21037/jxym.2019.03.05.

11. African Health Observatory (AHO), World Health Organization (WHO). Factsheet of Health Statistics World Health Organization (WHO) Regional Office for Africa for 2018 [cited 2020 June 27]. Available from: http://www.aho.afro.who.int/profiles_information/index.php/Tanzania:Health_fi-nancing_system/cite_note-five-0.

12. Government of the United Republic of Tanzania, United Nations International Children’s Emergency Fund (UNICEF), Tanzania Health Budget Brief 2018 The United Republic of Tanzania: UNICEF; 2018 [cited 2020 June 27]. Available from: https://www.unicef.org/tanzania/sites/unicef.org.tanzania/files/2018-12/UNICEF-Tanzania-2018-Health-Budget-Brief.pdf.

13. Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berdichevski F, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research. 2013;15(5):R92. DOI: 10.1186/bcr3493 PMID: 24286369.

14. Alwan A, Armstrong T, Betchter D, Branca F, Chisholm D, Ezzati M, et al. Global status report on noncommunicable diseases 2010. Geneva, Switzerland: World Health Organization; 2011. 176 p.

15. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: 10.3322/caac.21492 PMID: 30207593.

16. Mabula JB, McHembe MD, Chalya PL, Gitti G, Chandika AB, Rambau P, et al. Stage at diagnosis, clinicopathological and treatment patterns of breast cancer at Bugando Medical Centre in north-western Tanzania. Tanzan J Health Res. 2012;14(4):1-14. DOI: 10.4314/thrb.v14i4.6 PMID: 26591725.

17. World Health Organization. Noncommunicable diseases country profiles 2014 Geneva, Switzerland: World Health Organization 2014 [updated July 2014; cited 2020 May]. Available from: https://www.who.int/nmh/publications/ncd-profiles-2014/en/.

18. World Health Organization. Noncommunicable diseases country profiles 2018 Geneva, Switzerland: World Health Organization; 2018 [updated September 2018; cited 2020 May 6]. Available from: https://apps.who.int/iris/handle/10665/274512.

19. Sasco AJ. Epidemiology of breast cancer: an environmental disease? APMS. 2001;109(5):321-32. DOI: 10.1034/j.1600-0463.2001.090501.x PMID: 11478680.

20. Castello A, Martin M, Ruiz A, Casas AM, Baena-Cana-da JM, Lope V, et al. Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGECAM Case-Control Study. PLoS One. 2015;10(5):e0126096. DOI: 10.1371/journal.pone.0126096 PMID: 25978407.

21. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr., et al. Alcohol, tobacco and breast cancer—collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87(11):1234-45. DOI: 10.1038/sj.bjc.6600596 PMID: 12439712.

22. World Health Organization. United Republic of Tanzania: WHO Country Cooperation Strategy 2016-2020. Brazzaville, Republic of Congo: WHO Regional Office for Africa; 2016. 48 p.

23. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. DOI: 10.3322/caac.21077 PMID: 21296855.

24. Jones SA. Global burden of Non Communicable Diseases. Aust Nurs Midwifery J. 2015;23(4):48. PMID: 2665654.

25. Latest global cancer data [press release]. Lyon, France: International Agency for Research on Cancer (IARC), 12 September 2018.

26. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study 2015. JAMA Oncol. 2017;3(4):524-48. DOI: 10.1001/jamaoncol.2016.5688 PMID: 27918777.

27. World Health Organization. Cancer Geneva, Switzerland: World Health Organization; 2018 [updated 2018 September 12; cited 2020 June 27]. Available from: http://www.
28. Ministry of Health, Community Development, Gender, Elderly and Children. National Guidelines for Early Diagnosis of Breast Cancer and Referral for Treatment. Dar es Salaam, United Republic of Tanzania: Ministry of Health, Community Development, Gender, Elderly and Children; 2018. 10-20 p.

29. Rambau P, Masalu N, Jackson K, Chalya P, Serra P, Bravaccini S. Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients. BMC Res Notes. 2014;7:399. DOI: 10.1186/1756-0500-7-399 PMID: 24964871.

30. Burson AM, Soliman AS, Ngoma TA, Mwaiselage J, Ogweyo P, Eissa MS, et al. Clinical and epidemiologic profile of breast cancer in Tanzania. Breast Dis. 2010;31(1):33-41. DOI: 10.3233/BD-2009-0296 PMID: 21109721.

31. Mbonde MP, Amir H, Akslen LA, Kitinya JN. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population. East Afr Med J. 2001;78(7):360-6. DOI: 10.4314/eami.v78i7.9009 PMID: 11957260.

32. Ministry of Health, Community Development, Gender, Elderly and Children. Tanzania Breast Health Care Assessment: An assessment of breast cancer early detection, diagnosis and treatment in Tanzania. Seattle, WA, USA: Ministry of Health, Community Development, Gender, Elderly and Children; 2017. 62 p.

33. Mwakigonja AR, Lushina NE, Mwanga A. Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Mulhimbili National Hospital, Dar es salaam, Tanzania. Infect Agent Cancer. 2017;12:60. DOI: 10.1186/s13027-017-0170-5 PMID: 29142588.

34. Black E, Richmond R. Improving early detection of breast cancer in sub-Saharan Africa: why mammography may not be the way forward. Global Health. 2019;15(1):3. DOI: 10.1186/s13098-018-0464-6 PMID: 30621753.

35. Mansouri H, Mnango LF, Magorosa EP, Sauli E, Mpolya EA, Ki-67, p53 and BCL-2 Expressions and their Association with Clinical Histopathology of Breast Cancer among Women in Tanzania. Sci Rep. 2019;9(1):9918. DOI: 10.1038/s41598-019-46184-x PMID: 32189309.

36. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc.; 2017.

37. Eble JN, Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 1 ed. Lyon: World Health Organization; 2003. 432 p.

38. Allen J, Burrell C, Caplice C, Collins D, McGreal P, Purcell J. Oncology. Breast Cancer. United Kingdom: Physiopedia; 2017-2018. Atlanta: American Cancer Society, Inc.; 2017.

39. Silverberg SG. Atlas of Breast Pathology. Philadelphia: W.B. Saunders; 2002. 206 p.

40. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Breast Cancer. Version 4.2020. Pennsylvania, USA: NCCN; 2020 [updated 2020 May 8; cited 2020 June 28]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

41. Shapochka DO ZS, Gnidyuk MI Expression of Molecular Markers in Tumours of Patients with Breast Cancer. J Cytol Histol. 2013;4(4):184. DOI: 10.4172/2157-7099.1000184.

42. Strand C, Bak M, Borgquist S, Chebil G, Falck A-K, Fjällskog M-L, et al. The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer. SpringerPlus. 2013;2(1):111. DOI: 10.1186/2193-1801-2-111.

43. Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014;5(3):382-92. DOI: 10.5306/wjco.v5.i3.382 PMID: 25114853.

44. Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espie M, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer. 2013;132(5):1227-31. DOI: 10.1002/ijc.27767 PMID: 22886769.

45. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res. 2002;4(2):70-6. DOI: 10.1186/bcr426 PMID: 11879567.

46. Hwang KT, Han W, Kim J, Moon HG, Oh S, Song YS, et al. Prognostic Influence of BCL2 on Molecular Subtypes of Breast Cancer. J Breast Cancer. 2017;20(1):54-64. DOI: 10.4048/jbc.2017.20.1.54 PMID: 28382095.

47. Hwang K-T, Kim K, Chang JH, Oh S, Kim YA, Lee JY, et al. BCL2 regulation according to molecular subtype of breast cancer by analysis of the cancer genome atlas database. Cancer Res Treat. 2018;50(3):658-69. DOI: 10.4143/crt.2017 PMID: 28701032.

48. Nalwoga H. Molecular Markers in Breast Carcinoma. A study with focus on molecular phenotypes, angiogenesis and stem cells in an African population. [Norway]: University of Bergen; 2010. 140 p.

49. Kim T, Han W, Kim MK, Lee JW, Kim J, Ahn SK, et al. Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. J Breast Cancer. 2015;18(1):16-21. DOI: 10.4048/jbc.2015.18.1.16 PMID: 25834606.

50. Li LT, Jiang G, Chen Q, Zheng JN. Ki67 is a promising molecular target in the diagnosis of cancer (review). Mol Med Rep. 2015;11(3):1566-72. DOI: 10.3892/mmr.2014.2914 PMID: 25384676.

51. Mansouri AR, Rabiel H, Mbembati NA, Lema LE. The pattern of prognostic and risk indicators among women with breast cancer undergoing modified radical mastectomy in Dar es Salaam, Tanzania. Infect Agent Cancer. 2016;11:28. DOI: 10.4143/jbc.2017.20.1.54 PMID: 27366204.

52. Alwash Z, Henke O, Serventi F, Kantelhardt EJ. Staff Perspectives Toward Challenges in a Newly Established Cancer Center in Tanzania: A Qualitative Study. J Glob Oncol. 2019;5:1-8. DOI: 10.1002/jgo.18.00246 PMID: 30943098.

53. Rabinowitz B. Interdisciplinary breast cancer care: declaring and improving the standard. Oncology (Williston Park). 2004;18(10):1263-8; discussion 8-70. PMID: 15169927.
54. Ogweyo PA. Feasibility and cost effectiveness of using fine needle aspiration biopsies for the diagnosis of palpable breast masses in peripheral hospitals in Tanzania. [A dissertation in partial fulfillment of the Master of Medicine degree in Anatomical Pathology.]. [Dar es Salaam, Tanzania]: Dar es Salaam University 1996. p.

55. Chalya PL, Lema MK, Mabula JB, Rambau P, McHembe MD, Masalu N, et al. Triple assessment as a preoperative diagnostic tool for breast cancer at Bugando Medical Centre in northwestern Tanzania. Tanzan J Health Res. 2013;15(4):223-9. DOI: 10.4314/thrb.v15i4.3 PMID: 26591697.

56. Pace LE, Shulman LN. Breast cancer in sub-Saharan Africa: challenges and opportunities to reduce mortality. Oncologist. 2016;21(6):739-44. DOI: 10.1634/theoncologist.2015-0429 PMID: 27091419.

57. Rambau PF, Chalya PL, Manyama MM, Jackson KJ. Pathological features of Breast Cancer seen in Northwestern Tanzania: a nine years retrospective study. BMC Res Notes. 2011;4:214. DOI: 10.1186/1756-0500-4-214 PMID: 21696617.

58. World Health Organization. Assessing national capacity for the prevention and control of noncommunicable diseases: report of the 2015 global survey. Geneva, Switzerland: World Health Organization; 2016. 132 p.

59. Silverstein A, Sood R, Costas-Chavarri A. Breast cancer in Africa: limitations and opportunities for application of genomic medicine. Int J Breast Cancer. 2016;2016:4792865. DOI: 10.1155/2016/4792865 PMID: 27413551.

60. Kabel AM. Tumor markers of breast cancer: New perspectives. J Oncol Sci. 2017;3(1):5-11. DOI: 10.1016/j.jons.2017.01.001.

61. Bravaccini S, Ravaiolì S, Amadori D, Scarpi E, Puccetti M, Rocca A, et al. Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? Front Endocrinol (Lauzan). 2018;9:137. DOI: 10.3389/fendo.2018.00137 PMID: 29651273.

62. Pfefferle AD, Agrawal VN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, et al. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech. 2016;9(7):749-57. DOI: 10.1242/dmm.025239 PMID: 27149990.